Nebenwirkungen · Mixtard
Mixtard 30 40 international units/ml suspension for injection in vial. Mixtard 30 100 international units/ml suspension for injection in vial. Mixtard 30 Penfill 100 international units/ml suspension for injection in cartridge. Mixtard 30 InnoLet 100 international units/ml suspension for injection in pre-filled pen. Mixtard 30 FlexPen 100 international units/ml suspension for injection in pre-filled pen. · Abschnitt 4.8 · PDF-Seite 7–8
HOS-111178 · Präparat HOS-093463
In clinical trials, the frequency of hypoglycaemia varied with patient population, dose regimens and level of glycaemic control. 7 Skin and subcutaneous tissue disorders Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-01-24T16:35:00Z · SHA-256 6f5b0cbd7924d3f8fc676646a82c37907875f834271b75ee6e7920db1e310786 · Passage d6b60547e0d42d816880f58baa14fd15813dec4f34090bf7ed804f53a4a7b84c · Zeichen 3219–3730 im Abschnitt